SMO Clinplus: 2023 Annual Equity Distribution Implementation Notice
SMO Clinplus: Legal Opinion of Beijing Guofeng (Shanghai) Law Firm on the 2023 Annual General Meeting of Shareholders of Prius (Shanghai) Pharmaceutical Technology Development Co., Ltd.
SMO Clinplus: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
SMO Clinplus: 301257 Pryce Research Activity Information20240517
SMO Clinplus: Announcement on the change in shareholding ratio of shareholders holding 5% or more of the company's shares to 1%
SMO Clinplus: Prompt Notice on Convening the 2023 Annual General Meeting of Shareholders
SMO Clinplus: 301257 Prius Investor Relations Management Information 20240510
SMO Clinplus: 301257 Pryce Research Activity Information 20240430
SMO Clinplus: External guarantee decision management system (April 2024)
SMO Clinplus: Huatai United Securities Co., Ltd.'s inspection opinion on the extension of some fund-raising projects of Prius (Shanghai) Pharmaceutical Technology Development Co., Ltd.
SMO Clinplus: Announcement on the 2023 Profit Distribution Plan
SMO Clinplus: Huatai United Securities Co., Ltd. inspection opinions on the storage and use of funds raised by Prius (Shanghai) Pharmaceutical Technology Development Co., Ltd. in 2023
SMO Clinplus: Report on the performance of supervisory duties of accounting firms by the Audit Committee of the Board of Directors in 2023
SMO Clinplus: Board of Directors Rules of Procedure (April 2024)
SMO Clinplus: 2023 Annual Report Summary
SMO Clinplus: On the 2023 Performance Evaluation Report of Accounting Firms
SMO Clinplus: Notice on changing the company's registered capital, amending the “Articles of Association”, and registering industrial and commercial changes
SMO Clinplus: The Board's special opinion on the sole director's independence assessment
SMO Clinplus: Notice on applying for credit lines from banks
SMO Clinplus: Board Remuneration and Assessment Committee Work Rules (April 2024)
No Data